Core Viewpoint - Investors in BridgeBio Pharma Inc (BBIO) have new options available for May 2026 expiration, presenting potential opportunities for higher premiums in options trading due to the time value associated with the contracts [1] Options Analysis - The put contract at the $52.50 strike price has a current bid of $6.50, allowing investors to purchase the stock at an effective cost basis of $46.00 if sold [2] - The $52.50 strike represents a 1% discount to the current trading price, with a 63% chance of expiring worthless, potentially yielding a 12.38% return on cash commitment or 18.99% annualized [3] - The call contract at the $57.50 strike price has a current bid of $6.70, offering a total return of 20.74% if the stock is called away at expiration [4] - The $57.50 strike represents an 8% premium to the current trading price, with a 45% chance of expiring worthless, which could yield a 12.60% boost in returns or 19.33% annualized [7] Volatility Insights - The implied volatility for both the put and call contracts is approximately 57%, while the actual trailing twelve-month volatility is calculated at 52% [8]